Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Genewiz Inc. Sz is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a narrow prosecution footprint. In the biotech field, such a focused profile typically indicates that the company is pursuing a specific technical improvement under the guidance of a single specialized USPTO division.
LEE, HOI YAN NMN is the busiest examiner for the portfolio, with 1 pending office action under review. As the total count of pending actions is 1, this examiner is the primary authority for the company's current patent applications. The 1 distinct art unit involved will determine the examination timeline and procedural standards. Success for Genewiz Inc. Sz depends on meeting the specific technical requirements of LEE, HOI YAN NMN, as no other examiners are currently providing feedback on the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021956 | AMMONOLYSIS SOLUTION AND AMMONOLYSIS METHOD | LEE, HOI YAN NMN | 63d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021956 | AMMONOLYSIS SOLUTION AND AMMONOLYSIS METHOD | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | 63d | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenewiz Inc. Sz has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hoi Yan Nmn Lee has the most, with 1 of Genewiz Inc. Sz's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
